二甲双胍与结直肠癌

doi:10.3760/cma.j.issn.1673422X.2016.07.016

摘要/Abstract

摘要： 二甲双胍是治疗2型糖尿病的一线用药，除发挥降糖作用外，还具有抑制结直肠癌等肿瘤细胞增殖的作用。近年来大量证据表明二甲双胍能降低结直肠癌等肿瘤的发病风险及死亡率，其机制主要包括激活单磷酸腺苷活化的蛋白激酶通路，干扰细胞周期，改善胰岛素抵抗，抑制炎症反应，杀伤结直肠癌干细胞等。

关键词: 结直肠肿瘤, 二甲双胍, 糖尿病

Abstract: Mefformin is the firstline oral medicine used to treat type 2 diabetes．Besides its glucoselowering effect, Mefformin can inhibit the proliferation of cancer cells, especially colorectal cancer cells. In recent years, there is mounting evidence that mefformin could reduce the risk and mortality of colorectal cancer, and its mechanism includes activating AMP activated protein kinase pathway, interfering with cell cycle, reducing insulin resistance, inhibiting the inflammatory response and killing colorectal cancer stem cells, etc.

Key words: Colorectal neoplasms, Metformin, , Diabetes mellitus

赵晓彤, 陈明卫. 二甲双胍与结直肠癌[J]. 国际肿瘤学杂志, 2016, 43(7): 541-544.

ZHAO Xiao-Tong, CHEN Ming-Wei. Metformin and colorectal cancer[J]. Journal of International Oncology, 2016, 43(7): 541-544.

参考文献

［1］ Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus［J］. Int J Cancer, 2012, 131(3): 752759. DOI: 10.1002/ijc.26421. ［2］ Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals［J］. BMC Cancer, 2011, 11: 20. DOI: 10.1186/147124071120. ［3］ Cardel M, Jensen SM, Pottegrd A, et al. Longterm use of metformin and colorectal cancer risk in type Ⅱ diabetics: a populationbased casecontrol study［J］. Cancer Med, 2014, 3(5): 14581466. DOI: 10.1002/cam4.306. ［4］ Sehdev A, Shih YC, Vekhter B, et al. Metformin for primary colorectal cancer prevention in patients with diabetes: a cascontrol study in a US population［J］. Cancer, 2015, 121(7): 10711078. DOI: 10.1002/cncr.29165. ［5］ Zakikhani M, Dowling RJ, Sonenberg N, et al. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMPKactivated protein kinase［J］. Cancer Prev Res (Phila), 2008, 1(5): 369375. DOI: 10.1158/19406207.CAPR080081. ［6］ Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice［J］. Cancer Sci, 2008, 99(11): 21362141. DOI: 10.1111/j.13497006.2008.00933.x. ［7］ Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethaneindused colorectal aberrant crypt foci by activating AMPactivated protein kinase［J］. Mol Carcinog, 2010, 49(7): 662671. DOI: 10.1002/mc.20637. ［8］ Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a shortterm clinical trial［J］. Cancer Prev Res (Phila), 2010, 3(9): 10771083. DOI: 10.1158/19406207.CAPR100186.. ［9］ Tao R, Gong J, Luo X, et al. AMPK exerts dual regulatory effects on the PI3K pathway［J］. J Mol Signal, 2010, 5(1): 1. DOI: 10.1186/1750218751. ［10］ Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferationimplications for a novel treatment strategy［J］. Gynecol Oncol, 2010, 116(1): 9298. DOI: 10.1016/j.ygyno.2009.09.024. ［11］ Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53deficient tumor cell growth［J］. Cancer Res, 2007, 67(14): 67456752. DOI: 10.1158/00085472.CAN064447. ［12］ Algire C, Amrein L, Aakikhani M, et al. Metformin blocks the stimulative effect of a highenergy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase［J］. Endocr Relat Cancer, 2010, 17(2): 351360. DOI: 10.1677/ERC090252. ［13］ Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMPactivated protein kinase connects energy sensing to mitophagy［J］. Science, 2011, 331(6016): 456461. DOI: 10.1126/science.1196371. ［14］ Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2deoxyglucose induces p53dependent apoptosis in prostate cancer cells［J］. Cancer Res, 2010, 70(6): 24652475. DOI: 10.1158/00085472.CAN092782. ［15］ Zhou XZ, Xue YM, Zhu B, et al. Effects of metformin on proliferation of human colon carcinoma cell line SW480［J］. Nan Fang Yi Ke Da Xue Xue Bao, 2010, 30(8): 19351938, 1942. ［16］ OliverasFerraros C, VazquezMartin A, Menendez JA. Genomewide inhibitory impact of the AMPK activator metformin on ［kinesins, tubulins, histones, auroras and pololike kinases］ Mphase cell cycle genes in human breast cancer cells［J］. Cell Cycle, 2009, 8(10): 16331636. DOI: 10.4161/cc.8.10.8406. ［17］ Dowling RJ, Niraula S, Stambolic V, et al. Metformin in cancer: translational challenges［J］. J Mol Endocrinol, 2012, 48(3): R3143. DOI: 10.1530/JME120007. ［18］ Gallagher EJ, LeRoith D. The proliferating role of insulin and insulinlike growth factors in cancer［J］. Trends Endocrinol Metab, 2010, 21(10): 610618. DOI: 10.1016/j.tem.2010.06.007. ［19］ Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer［J］. Endocrinology, 2011, 152(7): 25462551. DOI: 10.1210/en.20110231. ［20］ Chi F, Wu R, Zeng YC, et al. Circulation insulinlike growth factor peptides and colorectal cancer risk: an updated systematic review and metaanalysis［J］. Mol Biol Rep, 2013, 40(5): 35833590. DOI: 10.1007/s110330122432z. ［21］ Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokineinduced nuclear factor kappaB activation via AMP activated protein kinase activation in vascular endothelial cells［J］. Hypertension, 2006, 47(6): 11831188. DOI: 10.1161/01.HYP.0000221429.94591.72. ［22］ Hopkins MH, Flanders WD, Bostick RM. Associations of circulating inflammatory biomarkers with risk factors for colorectal cancer in colorectal adenoma patients［J］. Biomark Insights, 2012, 7: 143150. DOI: 10.4137/BMI.S10092. ［23］ Arai M, Uchiba M, Komura H, et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor1 expression in human monocytes in vitro［J］. J Pharmacol Exp Ther, 2010, 334(1): 206213. DOI: 10.1124/jpet.109.164970. ［24］ Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types［J］. Cancer Res, 2011, 71(9): 31963201. DOI: 10.1158/00085472.CAN103471. ［25］ Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth［J］. Proc Natl Acad Sci USA, 2013, 110(3): 972977. DOI: 10.1073/pnas.1221055110. ［26］ NangiaMakker P, Yu Y, Vasudevan A, et al. Metformin: a potential therapeutic agent for recurrent colon cancer［J］. PLoS One, 2014, 9(1): e84369. DOI: 10.1371/journal.pone.0084369. ［27］ Kim TI. Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer［J］. World J Gastroenterol, 2014, 20(14): 38353846. DOI: 10.3748/wjg.v20.i14.3835. ［28］ Bodmer M, Becker C, Meier C, et al. Use of metformin is not associated with a decreased risk of colorectal cancer: a casecontrol analysis［J］. Cancer Epidemiol Biomarkers Prev, 2012, 21(2): 280286. DOI: 10.1158/10559965.EPI110992T. ［29］ Bodmer M, Becker C, Jick SS, et al. Metformin does not alter the risk of lung cancer: a casecontrol analysis［J］. Lung Cancer, 2012, 78(2): 133137. DOI: 10.1016/j.lungcan.2012.08.010. ［30］ Sui X, Xu Y, Yang J, et al. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5fluorouracil through AMPK activation［J］. PLoS One, 2014, 9(5): e97781. DOI: 10.1371/journal.pone.0097781. ［31］ Martin MJ, Hayward R, Viros A, et al. Metformin accelerates the growth of BRAFV600Edriven melanoma by upregulating VEGFA［J］. Cancer Discov, 2012, 2(4): 344355. DOI: 10.1158/21598290.CD110280. ［32］ Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDAMB435 breast cancer model［J］. Breast Cancer Res Treat, 2009, 113(1): 101111. DOI: 10.1007/s1054900899165.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良. 循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江. 炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红. AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福. FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.